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Abstract 
N-Acetylmuramyl-L-alanine amidase (EC 3.5.1.28) cleaves the amide bond between N-acetyl muramic acid and L-alanine in the 
peptide side chain of different peptidoglycan products. The enzyme was purified from human plasma using a three-step column 
chromatography procedure. Monoclonal antibodies were produced against he purified human enzyme. By coupling of a high affinity 
monocional antibody to sepharose beads an immunoadsorbent column was prepared. Using this second purification method it was 
possible to purify large m'nounts of the amidase from human plasma in a single step. SDS-PAGE showed one single band of 70 kDa and 
two-dimensional electrophoresis showed the presence of multiple isomeric forms of the protein with pI between 6.5 and 7.9. Two 
different methods were used for determination of substrate specificity, a HPLC method separating peptidoglycan monomers from the 
reaction products after incubation with amidase and a colorimetric method when high molecular weight peptidoglycan was used as a 
substrate for amidase. It is shown that the disaccharide t tra peptide, disaccharide penta peptide and the anhydro disaccharide t trapeptide 
are good substrates for the amidase and that muramyl dipeptide and disaccharide dipeptide are not a substrate for the amidase. Using one 
of the monoclonal ntibodies against he amidase it was shown in FACScan analysis that N-acetylmuramyl-L-alanine amidase is present 
in granulocytes but not in monocytes from unstimulated peripheral blood of a healthy donor. The presence of N-acetylmuramyl-L-alanine 
amidase in granulocytes is a novel finding and perhaps important for the inactivation of biologically active peptidoglycan products till 
present after hydrolysis by lysozyme. 
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1. Introduction 
Peptidoglycan polymers, oligomers and monomers have 
potent biological effects. An important factor in the induc- 
tion of the biological effects is the ability of the peptido- 
glycan products to persist in human tissues. Bacterial cell 
wall products can be degraded by 3 different human 
enzymes: lysozyme [1], /3-N-acetylglucosaminidase [2] and 
the not well characterised N-acetylmuramyl-L-alanine ami- 
dase (NAMLAA). This NAMLAA hydrolyses peptidogly- 
can by cleaving the lactamide bond between N-acetyl 
muramic acid and L-alanine in the peptide side chain of the 
peptidoglycan molecule. Bordetel la  pertuss is  tracheal cy- 
Abbreviations: NAMLAA, N-acetylmuramyl-L-alanine amidase; 
SDS-PAGE, Sodium dodeCyl sulfate-polyacrylamide gel lectrophoresis; 
HPLC, High performance liquid chromatography; pl, Isoelectric point 
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totoxin is an anhydro-disaccharide tetrapeptide peptidogly- 
can monomer which is capable of reproducing the respira- 
tory cytopathology observed uring pertussis [3,4]. NAM- 
LAA is able to degrade this anhydro monomer very rapidly 
in vitro and might be the most important enzyme involved 
in the degradation of the tracheal cytotoxin in vivo. We 
hypothesize that this amidase, which we found in all 
human sera tested until now [5], plays an important role in 
the degradation and inactivation of biologically active 
peptidoglycan polymers and monomers in human tissue. 
Amidase (NAMLAA) activity in human serum was first 
described by Ladesi~ et al. in 1981 [6]. One year later 
Valinger et al. from the same group partially purified 
NAMLAA from human and mouse serum and defined its 
enzymatic activity [7]. In the present study we describe 
two methods for the purification of NAMLAA from hu- 
man plasma. The first method is based on DEAE, heparin 
sepharose and hydroxylapatite column chromatography. 
The protein obtained by this three-step method was used to 
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raise monoclonal antibodies against the enzyme. With 
these antibodies an immunoadsorbent affinity column was 
prepared with which amidase was purified in one single 
step with a 36% yield of the enzymatic activity. 
solution in 10 mM sodium acetate buffer, pH 5.6. Peptido- 
glycan concentrations vary between different experiments. 
2.3. Detection qf' NAMLAA activit)' by a colorimetric 
method 
2. Material and methods 
2.1. Purification of NAMLAA with three-step rocedure 
300 ml human plasma was dialyzed 3 times against 2 I 
25 mM sodium phosphate buffer pH 7.5. After dialysis it 
was centrifuged for 15 rain at 20 000 X g. The supernatant 
was then loaded onto a 500 ml DEAE sepharose 4B 
(Pharmacia) column. The column was washed with 8 1 25 
mM sodium phosphate buffer pH 7.5 until no more protein 
could be eluted. Elution of the amidase containing fraction 
was performed by changing the buffer to a 25 mM sodium 
phosphate buffer with 0.5 M NaC1. Amidase-containing 
fractions were pooled and dialyzed 3 times against 25 mM 
sodium phosphate buffer pH 7.5 and loaded onto a 50 ml 
heparin sepharose C1-4B column (Pharmacia). The column 
was washed with 10 column volumes of the sodium phos- 
phate buffer until the eluate did not contain any protein. 
Elution was performed using a linear gradient of 300 ml 
sodium phosphate pH 7.5 with 300 ml sodium phosphate 
pH 7.5 with 0.25 M NaCI. Amidase-containing fractions 
were pooled and dialyzed 3 times against 2 1 25 mM 
sodium phosphate pH 6.8 and loaded onto a 15 ml hy- 
droxylapatite (Biorad) column. Amidase does not bind to 
this column. The flow through was collected and dialysed 
against 20 mM NH4HCO 3 pH 8.0. All steps were per- 
formed in a cold room (4°C). The NAMLAA activity in 
the samples was determined using the colorimetric assay 
described below. 
2.2. Peptidoglycan substrates 
Peptidoglycan monomers from Brevibacterium dicari- 
catum (ATCC 14020) GlcNAc-MurNAc-L-Ala-D-isoGIn- 
m-Dpm]-(D)-amide-(L)-D-Ala-D-Ala pentapeptide, and Glc- 
NAc-MurNAc-L-Ala-D-isoGln-m-Dpm-o-Ala tetrapeptide 
were prepared as described by Hazenberg and de Visser 
[51. 
MurNAc-L-Ala-D-isoGlu (MDP) (Sigma), GlcNAc- 
MurNAc-L-Ala-D-isoGlu (GMDP) (Calbiochem corp), 
GlcNAc-MurNAc-anhydro-L-Ala-D-Glu-m-Dpm-D-Ala 
(anhydro disaccharide-tetrapeptide) isolated from Es- 
cherichia coli was a kind gift from A. Dijkstra, Hoffman 
La Roche. 
E. coli, B. divaricatum, Eubacterium aerofaciens, Bifi- 
dobacterium adolescentis and Streptococcus pyogenes pep- 
tidoglycans were prepared according to Severijnen et al. 
[8]. Micrococcus lysodeikticus was obtained from Sigma. 
The polymeric peptidoglycans were degraded by incubat- 
ing 250 /zg/ml overnight with a 25 /zg/ml lysozyme 
Amidase activity was determined as described by 
Hazenberg and de Visser [5] with some modifications. The 
method is based on determination of the increase of a free 
lactyl group in the peptidoglycan substrate due to the 
removal of the peptide side chain. Peptidoglycan monomers 
from B. dicaricatum (ATCC 14020) were used as a sub- 
strate. 200/.tl amidase sample and 200/zl substrate diluted 
in 20 mM NH4HCO 3 pH 8.0 to a final concentration of 
500 htg muramic acid/ml were incubated for 15 rain at 
37°C. The reaction was stopped by adding 200 /.tl 1 M 
NaOH and incubating for 30 rain. at 37°C. For determina- 
tion of background, substrate was incubated with buffer for 
15 rain at 37°C. In these samples muramic acid was 
determined as follows. 100 /.tl sample+l  ml (conc) 
H2SO 4 was boiled for 3.5 rain and rapidly cooled in ice 
water. Then 10 /.tl 0.16 M CuSO 4 -5H20 and 20 /xl 0.09 
M p-hydroxydiphenyl in ethanol were added. After a 30 
min incubation period at 30°C the absorbance at 570 nm 
was measured using a Titertek Multiskan (Flow Lab., 
Irvine, Scotland). 0-100 /zg/ml muramic acid solutions 
were used as standards. For determining the specific activ- 
ity of NAMLAA using polymeric peptidoglycan lower 
concentrations of peptidoglycan were used. 
2.4. Detection of NAMLAA activity by HPLC 
Substrate specificity was determined using B. divarica- 
turn GlucNAc-MurNAc-pentapeptide and tetrapeptide. 
Also MurNAc-L-Ala-D-isoGlu (MDP), GlcNAc-MurNAc- 
L-AIa-D-isoGlu (GMDP) (Calbiochem Corp.), GlucNAc- 
MurNAc[anhydro] tetrapeptide isolated from E. coli were 
used. 500 ~g/ml  samples were incubated with affinity- 
purified amidase in a final concentration of 1 /zg/ml 25 
mM NH4HCO 3 buffer, pH 8.0, at 37°C. For determination 
of the background the substrate was incubated with buffer. 
The reactions were stopped after 15 min by diluting the 
samples 10 times with 25 mM sodium phosphate pH 3.5 
(HPLC buffer A). Peak areas were used to calculate the 
enzymatic activity. 1 unit is defined as the amount of 
substrate (/zmol) hydrolysed per minute at pH 8.0, 37°C. 
Reversed phase HPLC was used for separation of the 
reaction products. 10 /.tl samples were analyzed using a 
Pharmacia-LKB 2248 single pump solvent delivery system 
and VWM 2141 UV-VIS monitor both connected to a 
computer working with HPLC manager software to control 
the pump, gradient mixer and UV-VIS detector operating 
at 205 ram. Integration and analysis of chromatograms was 
performed using the same software (Pharmacia, Sweden). 
The samples were separated using a Pharmacia Superfac 
Sephasil C18, 5 /.tm, 4 × 250 mm column. The flowrate 
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was 1 ml/min and the buffers were A: 25 mM sodium 
phosphate pH 3.50; B: 15% methanol in 25 mM sodium 
phosphate pH 4.70. At 0, 2, 10, 12.5, 13, 15 min the 
percentage B was 0, 0, 100, 100, 0, 0, respectively. 
For determination f K m and maximal rate of catalysis 
(V max), substrate concentrations were used between 2mM 
and 0.1 mM GlucNac-MurNAc-pentapeptide of B. divari- 
catum. The aminoacid and aminosugar composition of the 
separated peaks before and after amidase incubation was 
determined according to the method described in a previ- 
ous paper [9]. 
2.5. Preparation of monoclonal antibodies 
The purified amidase was used for preparing mono- 
clonal antibodies. A male Balb/c mouse was injected 
intraperitoneally with 50 /zg of NAMLAA in complete 
Freund's adjuvant. After 6 wk, the mouse received a 
booster of 10 /zg NAMLAA in incomplete Freund's adju- 
vant. After another 6 wk, the mouse received a second 
booster of l0 /xg amidase in incomplete Freund's adju- 
vant, intraperitoneally and 10 /xg amidase in PBS, intra- 
venously. Three days later, the mouse was sacrificed and 
cells isolated from popliteal, inguinal and axillary lymphn- 
odes and the spleen were fused with the Sp2/0 plasmacy- 
toma cell line in a ratio of 5:1 and 5:2 (spleen: Sp2/0) 
using standard procedures for the production of hybrido- 
mas [13]. Cells were seeded at a concentration of 8.10 4 
cells/well in the presence of human growth factor (40 
U/ml)  [10,11]. The supernatants of 3000 wells were tested 
for the production of antibodies against amidase in an 
ELISA. The amidase-positive supematants were tested in 
an isotype ELISA [12]. Only IgG-producing clones were 
used for further experiments. Monoclonal antibody AAA4 
showed the highest affinity for NAMLAA and was used 
for preparing a FITC-labeled monoclonal antibody (a- 
NAMLAA-FITC) and for preparing an immunoadsorbent 
column. 
2.6. Preparing immunoadsorbent column and purification 
of NAMLAA 
Monoclonal antibodies were purified over a 10 ml 
Immunopure Immobilized Protein G column (Pierce) using 
the standard protocol of the supplier. 7.2 mg of mono- 
clonal antibody AAA4 was dialyzed 3 times against 2 1 0.1 
M NaHCO 3 + 0.5 M NaCI and coupled to 2 g CNBr- 
activated Sepharose 4B (Pharmacia LKB Biotechnology) 
according to the protocol of the supplier. Human plasma 
(obtained from the blood bank Rotterdam) was dialyzed 
against PBS and diluted 2 times in PBS before it was 
loaded onto the column. The column was washed with 
PBS until no more protein was detected in the eluate. The 
amidase was eluted by changing the buffer to 0.1 M 
Gly-HCI, pH 3.0. The peak fractions were immediately 
dialyzed against 20 mM NH4HCO 3 pH 8.0. 
2.7. Immunofluorescence labeling, flow-cytometric analy- 
sis 
Labeling of AAA4 with fluorescent isothiocyanate 
(FITC) was performed according to standard procedures 
[13]. Human peripheral blood cells were stained for intra- 
cellular antigens according to Syrjil~i [14]. In short: 100/xl 
citrate blood was lysed and fixed by adding 2 ml of FACS 
lysing solution (Becton Dickinson) and incubating for 10 
min at room temperature. The cells were centrifuged and 
washed 2 times with PBS + 0.5% BSA. Then the mouse 
a-NAMLAA-FITC or rabbit a-human lysozyme (DAKO, 
ITK Diagnostics) were added and the mixture was incu- 
bated for 10 min at room temperature. The cells were 
washed 2 times with 2 ml PBS-BSA. The rabbit a-lyso- 
zyme-treated cells were incubated with the second anti- 
body goat-a-rabbit-FITC for 10 rain, washed 2 times with 
PBS-BSA and finally resuspended in 200 /xl FACS flow 
(Becton Dickinson). The analyses were performed with a 
FACScan cytofluorimeter (Becton Dickinson, Sunnyval, 
CA). 
2.8. SDS-polyacrylamide gel electrophoresis and im- 
munoblot analysis 
The amidase was subjected to 10% SDS-PAGE to 
check for purity. Affinity-purified amidase samples of 20 
/zl were boiled for 3 min together with 5/~1 loading buffer 
(60 mM Tris. HCI pH 6.8; 23% glycerol 3% SDS; 0.06% 
bromophenol blue; 10% fl-mercapto ethanol) 10 /zl of 
these samples were analyzed on 10% SDS-PAGE (Mini 
Protein, BioRad). Samples were visualized by Coomassie 
Blue staining or transferred to nitrocellulose in 25 mM 
Tris, 190 mM glycine and 20% methanol transfer buffer. 
Nitrocellulose sheets were blocked in low-fat milk for 30 
min and subsequently washed three times with 0.5% 
Tween-20 in PBS. Nitrocellulose sheets were then incu- 
bated for 1 h with monoclonal antibodies 500 times diluted 
in PBS-Tween at room temperature. Following three 
washes, goat anti-mouse IgG conjugated to alkaline phos- 
phatase (TAGO) was added in a 1000 times dilution and 
incubated for 1 hour at room temperature. The blot was 
washed three times with PBS-Tween and then three times 
with PBS. For visualization of antibody-antigen complexes 
the alkaline phosphatase substrate, nitroblue 
tetrazol ium/5-bromo-4-chloro indoxyl phosphate 
(NBT/BCIP), was used as described [20]. 
2.9. Two-dimensional electrophoresis 
25 p,1 of affinity-purified NAMLAA was mixed with 25 
/xl sample buffer (0.3% SDS, 200 mM dithiothreitol, 28 
mM Tris • HC1 and 22 mM Tris-base) and heated for 4 min 
at 100°C. Two-dimensional e ectrophoresis was performed 
with the Millipore Investigator system. We used am- 
pholytes with a pH range from 3-10 for the first dimen- 
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Table 1 
Purification of N-acetylmuramyl-L-alanine amidase from human plasma by three-step procedure 
Protein conc (mg/ml) Total protein (rag) Specific activity (U/rag) Yield (%) 
plasma 48.7 15.6 X 103 4.6 x 10 -2 100 
DEAE 13.6 2.7 X 102 0.11 41 
heparin 0.2 15.4 3.2 6.9 
hydroxylapatite 1.0 X 10 2 1.0 6.7 0.9 
Protein concentrations were determined according to the method of Bradford. Enzymatic activity was determined by the colorimetric assay (see Section 
2.3). 
sion. For the second dimension we used 10% Duracryl 
gels. Glyceraldehyde-3-phosphate dehydrogenase carbama- 
lytes (Pharmacia) were used as isoelectric-focussing mark- 
ers. Proteins were visualized with a silver staining tech- 
nique. All steps were performed according to the manufac- 
turer's instructions. 
2.10. Gel permeation chromatography 
A superdex 200 HR 10/30 column with 10 mm internal 
bore diameter and 30 cm length (V~ = 24 ml) was used 
(Pharmacia). The column was connected to a standard 
FPLC system (Pharmacia), consisting of a LCC chro- 
matography controller, two P-500 pumps, a MV-7 injector 
with a 200 /xl sample loop, a UV-1 monitor at 280 nM 
operating at 0.05 AUFS sensitivity and a FRAC 100 
fraction collector. Routinely, isocratic elution with PBS 
was used. Column selectivity was determined by using 
mixtures of molecular weight marker proteins (Pharmacia) 
ranging from 670 kDa to 17 kDa. 200 /xl purified NAM- 
LAA was injected on the column. Enzymatic activity was 
determined in the peak fractions. 
2.11. Immunohistochemistry 
Blood smears of a healthy person were fixed for 10 min 
in acetone. After rinsing in PBS with 0.2% bovine serum 
albumin (BSA), the smears were incubated for 1 h at room 
temperature with monoclonal antibody AAA3 (diluted 40 
/xg/ml in PBS-BSA) or, for control staining, an irrelevant 
monoclonal antibody of the same isotype and concentra- 
tion. Subsequently, the smears were rinsed in PBS-BSA 
and incubated for 30 min at room temperature with rabbit 
anti-mouse immunoglobulin (Z259, Dakopatts) diluted 1:20 
in PBS-BSA with 1% normal human serum. After rinsing 
in PBS-BSA, a 1:40 dilution of alkaline phosphatase- 
mouse-anti-alkaline phosphatase complex (APAAP, D651, 
Dakopatts, Denmark) was applied for 30 min. To develop 
the stain the smears were incubated for 30 min at room 
temperature with new Fuchsin substrate (Chroma), which 
stained positive cells red. After rinsing in distilled water 
the nuclei of the cells were stained blue by incubation for 
1 min with haematoxylin and rinsing in fresh water for 10 
min. Finally, the smears were mounted in Kaiser's glycerol 
gelatin (Merck). 
3. Results 
3.1. Purification of NAMLAA from human plasma 
Table 1 shows the purification scheme of the three step 
purification. The amidase activity in dialyzed and cen- 
trifuged plasma was 46 mU/mg protein. The final pure 
amidase had a specific activity of 6.7 U /mg protein. Most 
of the total activity was lost during this purification proce- 
dure (99%). Starting with 300 ml plasma it was possible to 
purify about 1 mg NAMLAA using this method. 
3.2. Monoclonal antibodies and immunoaffinity purifica- 
tion 
Six different monoclonal antibodies against NAMLAA 
were obtained. Monoclonal AAA4 showed the highest 
affinity for the human amidase in a competition ELISA 
(not shown) and was therefore used to prepare an im- 
munoadsorbent column. 7.2 mg purified monoclonal anti- 
body was coupled to CNBr-activated sepharose beads. The 
capacity of the column was sufficient for the 50 ml plasma 
used. No amidase activity could be detected in the flow- 
through when diluted plasma was applied to the column. 
After elution with 0.1 M Gly • HCI pH 3.0, pure amidase 
was eluted from the column. From 50 ml plasma it was 
possible to obtain 0.6 mg pure amidase. 
Table 2 
Purification of N-acetylmuramyl-L-alanine amidase from human plasma by immunoaffinity chromatography 
Protein conc (mg/ml) Total protein (mg) Specific activity (U/mg) Yield (%) 
plasma 48.7 2435 3.1 X 10 -2 100 
Immunoaffinity 0.1 0.6 46 34 
Protein concentrations were determined according to the method of Bradford. Enzymatic activity was determined by the HPLC method (see Section 2.4). 
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kD 
200 
116 
97.4 
66 
purified amidase solution obtained by this method con- 
tained a specific activity of 46 U/mg protein and 36% of 
the enzymatic activity was recovered. Therefore, by using 
the immunoadsorbent column it was possible to increase 
the yield 38-fold and the final product had a specific 
activity 6.9-fold higher compared with the three-step ro- 
cedure. 
45 3.3. SDS-polyacrylamide gel electrophoresis and im- 
munoblot analysis 
31 
21.5 
1 2 3 4 5 6 
Fig. 1. Polyacrylamide gel electrophoreses of purified N-acetylmuramyl- 
L-alanine-amidase. 10-/zl samples of three different concentrations were 
analyzed on 10% PAGE-SDS. Lane 1 is amidase purified using the 
three-step procedure. Lane 2 and 6 are molecular weight markers and lane 
3, 4 and 5 are 20, 40 and 100 /zg/ml dilutions (resp.) of 
immunoaffinity-purified amidase. NAMLAA is clearly shown as a single 
band of 70 kDa. The gels were stained with Coomassie Blue. 
Table 2 shows the purification scheme. The amidase 
activity in this dialyzed and centrifugated plasma was 31 
mU/mg protein, determined by the HPLC method. The 
Fig. 1 shows a 10% SDS-PAGE. Purified amidase is 
electrophoresed as a single band with a molecular mass of 
70 kDa. After deglycosylation by N-glycosidase-F diges- 
tion, the molecular mass decreased to 60 kDa (not shown). 
Western blot analysis of purified NAMLAA before and 
after deglycosylation showed that four of the six mono- 
clonal antibodies including AAA4, the antibody used for 
purification, were able to recognize NAMLAA in both 
forms. 
3.4. Two-dimensional electrophoresis 
Fig. 2 shows affinity-purified NAMLAA subjected to 
iso-electrofocussing  the first dimension and 10% poly- 
acrylamide gel electrophoresis in the second imension. At 
least 8 different isomeric forms are visible of this glyco- 
protein. The pI values vary between 7.0 and 7.9 although 
- 200 kD 
- 70  kD 
tD 
t~ 
E 
"5 
to ID 
o 
E 
$ 
6.5 7.2 7.9 8.3 
pl 
Fig. 2. Two-dimensional ~ ectrophoresis of affinity-purified NAMLAA. First dimension isoelectro-focussing  a pH range of 3-10 and second imension 
10% Duracryl electrophoresis eparation on molecular weight. Thirteen different isomeric forms of the glycoprotein are visible. The silverstained gel does 
not show any impurities. 
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Fig. 3. Reversed phase high performance liquid chromatography chromatogram of B. divaricatum disaccharide pentapeptide b fore (A) and after (B) 
incubation with NAMLAA. The large peak with retention time 12.8 min in A represents he disaccharide pentapeptide. The small peak with retention time 
11.8 min is the disaccharide t trapeptide. The large peak in B with retention time 2.8 rain (void volume) contains the peptide product released from the 
sugar moiety. The small peak at 5 rain contains the disaccharide, The difference in area of the peaks in A with the corresponding peaks in B is a direct 
measure for the amount of substrate degraded by NAMLAA. 
the main spots are in the 7.5-7.8 range. No impurities are 
visible after silver staining. 
3.5. Detection of NAMLAA acticity by HPLC 
NAMLAA activity was tested with different peptidogly- 
can products. Muramyl dipeptide (MDP) was tested be- 
cause this product is the smallest component of peptidogly- 
can known to posses biological activity. Harrison and Fox 
[15] described that MDP was degraded by human serum. 
We did not find this activity for the purified amidase. 
OON-acetyiglucosamine-N-acetylmuramic acid dipeptide 
(GMDP) was not a substrate for NAMLAA either. Disac- 
charide tetrapeptide and the anhydro-disaccharide tetra- 
peptide were good substrates for NAMLAA. The anhydro 
form was degraded four times slower than the non-anhydro 
disaccharide-tetrapeptide. The disaccharide-pentapeptide 
was degraded at the same velocity as the tetrapeptide, as
determined by HPLC analysis (Fig. 3). 
Using the B. divaricatum disaccharide pentapeptide asa 
Table 3 
NAMLAA activity related to differences in peptide bridges in peptidoglycan from 6 bacterial species 
Paptidoglycan Source Aminoacids in peptide bridge Specific activity (U/mg) 
E COH 
D-Ala 
J 
NAM-L-Ala-D-Glu-M-Dpm- 57 
B. divaricatum 
D-Ala 
NAM-L-A a-D- soGIn-M-Dpm- 111 
E. aerofaciens 
D-Ala 
NAM-L-Ala-D-Glu-L-Lys- 12.5 
B. ado/escentis 
D-Ala 
NAM-L-Ala-D-G u-L-Orn-A a-D-Asp-D-Ser- 
S. pyogenes 
D-Ala 
I 
NAM-L-Ala-D-G u-L-Lys-D-Ala-L-Thr-L-A a- 
M. lysodeikticus NAM-L-Ala-D-Glu-L-Lys-D-Ala-L-Lys-D-Glu-L-Ala- 
d ly Gly 
Enzymatic activity was determined with the colorimetric method (see Section 2.3). 
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Fig. 4. FACScan analysis of nucleated fraction from blood of a healthy donor. Based on sideward scatter human peripheral blood cell suspensions can be 
devided in three different populations. The lower population consists of lymphocytes, the middle population consists of monocytes and de upper population 
are the granulocytes. Granulocytes are positively stained by a-NAMLAA-FITC (C), monocytes and lymphocytes are not stained with this monoclonal 
antibody. PBS (A) and IgG-FITC (B) were used as negative controls• 
substrate the maximal rate of catalysis is 0.10 mmol/min 
and the K m value is 2.5 mM. 
3.6. Detection of NAMLAA activity by colorimetric assay 
Six different lysozyme-solubilized peptidoglycan sam- 
ples were incubated with NAMLAA. In Table 3 the differ- 
ences in the peptide bridges of the peptidoglycans are 
shown with the corresponding specific activity of NAM- 
LAA. B. adolescentis, S. pyogenes and M. lysodeikticus 
peptidoglycans are not degraded by NAMLAA. The sub- 
strate concentration was 350 /~g/ml based on the concen- 
tration muramic acid in the reaction mixture. 
3.7. Flow-cytometric analysis 
FACScan analysis of the nucleated cells from blood of 
a healthy donor were performed to determine if NAMLAA 
is produced by white blood cells. In Fig. 4 it is shown that 
granulocytes contain NAMLAA but monocytes do not. 
Lysozyme could be detected in both monocytes and granu- 
locytes (not shown). PBS and IgG-FITC were used as a 
negative control (Fig. 3A and 3B). 
3.8. Native molecular mass determination 
The selectivity curve used was: KAV = 2 .309-  0.378 
log M r 
v~-Vo vo-8 
KAV 
V t - V o 12.8 
where V~ is the elution volume, V o is void volume (8.0 ml) 
and V t is total volume (20.7 ml). The elution volume of 
the NAMLAA activity containing peak was 14.0 ml. 
Therefore the calculated molecular mass is 69 kDa _+ 10%. 
Which proves that the amidase is composed of one sub- 
unit. 
3.9. lmmunohistochemistry 
The immunohistochemical staining of the blood smears 
of a healthy person with monoclonal antibody AAA3 
showed a positive staining of the granulocytes. The 
mononuclear cells including monocytes were negative. No 
positive cells were found by using an irrelevant mono- 
clonal antibody with the same isotype and concentration. 
4. Discussion 
In 1990 Vanderwinkel et al published the purification of 
NAMLAA from human serum [16]. They found an enzyme 
of Mr 120.000-130.000 in native PAGE and two bands of 
57 kDa and 70 kDa under denaturating conditions and 
considered amidase to be a dimeric protein with pI of 
4.5-5.5. They also found the E. coli-derived MurNAc-tri- 
peptide to be a good substrate for the enzyme as well as 
some polymeric peptidoglycans. Because it was only pos- 
sible to purify very small amounts of amidase with their 
method and the properties of the enzyme did not always 
correspond with the protein we were purifying we started 
with the development of a large scale purification to make 
a good characterization f the enzyme possible. 
This study describes two methods for the purification of 
NAMLAA from human plasma. The purification with a 
NAMLAA specific immunoabsorbent column yielded a 
higher specific activity than the three-step column purifica- 
tion method. Apparently some of the amidase purified by 
the three-step method loses some of its activity during the 
different steps, because the specific activity is much lower 
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compared to the immunoaffinity-purified NAMLAA. Pu- 
rification of human NAMLAA can therefore best be car- 
fled out using the specific immunoabsorbent column. It is 
unknown if all the immunoaffinity-purified NAMLAA is 
still active. It is therefore not possible to determine xactly 
the concentration f NAMLAA in plasma, but it must be at 
least 10 /xg/ml plasma. This is similar to normal serum 
concentrations of lysozyme which varies from 7 to 20 
/zg/ml [ll. 
The pattern of dots obtained after two-dimensional elec- 
trophoresis indicates that the NAMLAA contains variable 
amounts of charged groups. It was shown that NAMLAA 
is a glycoprotein because the molecular mass decreased 
after incubating the enzyme with N-glycosidase F. This 
was confirmed by experiments where to some extent 
NAMLAA activity bound to Sambuccus Nigra Agglutinin 
(SNA) coupled to sepharose beads (results not shown). 
SNA has a specific affinity for oz-NeuNAc [2-6] GalNAc 
[17] which is a charged group. 
Enzymatic activity of the enzyme is not restricted to 
peptidoglycan monomers. After lysozyme degradation, 
polymers with molecular mass greater than 10 6 Da from 
E. coli and E. aerofaciens were degraded for more than 
80% depending on NAMLAA concentration and reaction 
time. The composition of the peptide side chains of these 
substrates differ widely starting from the third aminoacid, 
counted from MurNAc (Table 3). Therefore it seems obvi- 
ous that the first three aminoacids together with N- 
acetylmuramic a id are the most important in determining 
substrate specificity. After alkali hydrolysis of the N- 
acetylgroup of N-acetylmuramic a id, the remaining ly- 
copeptide is no longer degradable by NAMLAA. 
The six purified monoclonal antibodies against NAM- 
LAA all have different affinities for amidase. 3 out of 6 
recognize NAMLAA in Western blot (data not shown). 
Flow-cytometric analysis of blood using a FITC-labeled 
monoclonal antibody against NAMLAA showed that gran- 
ulocytes contain NAMLAA. This to our knowledge novel 
finding makes it very likely that the enzyme is involved in 
degrading peptidoglycan products in blood and tissues, 
which could be liberated during infections or absorbed 
from the gut. The monoclonal antibodies are currently 
being used to screen a human cDNA expression library in 
order to identify the gene coding for the enzyme. 
Peptidoglycan is a polymer found in all bacterial cell 
walls. Biological activities of peptidoglycan are multifold. 
It has many biological effects in common with LPS but it 
is also able to cause chronic inflammation [18]. Peptido- 
glycan monomer anhydromuramyl dipeptide possesses 
sleep-inducing capacity [19]. All these biological activities 
of peptidoglycan monomers/polymers are likely to be 
susceptible to degradation by amidase. Further research 
will be done to study the influence of amidase on the 
biological activities of peptidoglycan. The relatively sim- 
ple method described in this paper for obtaining large 
amounts of pure NAMLAA will make it possible to study 
this human enzyme in greater detail. 
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